Novo Nordisk A/S
This study is testing whether CagriSema is safe and works well in adults with high blood pressure and excess body weight. Participants will receive CagriSema, semaglutide, cagrilintide, or placebo, and treatment will be assigned by chance. CagriSema and cagrilintide are investigational medicines, while semaglutide is already available by prescription.
Inclusion Criteria: * Male or female (sex at birth). * Age 18 years or above at the time of signing the informed consent. * Resting in-office SBP of 140-160 mmHg (both inclusive) at screening (V1-Optional/V1) and the Run-in visit. Systolic blood pressure will be calculated as the mean of the second and third consecutive readings of triplicated blood pressure readings collected at 2-minute intervals with the blood pressure monitor provided by the Sponsor. * Body mass index greater than or equal to (\>=) 30.0 kilograms per metre square (kg/m\^2) at screening. * Not receiving Sodium-Glucose Cotr…
CagriSema will be administered subcutaneously.
Semaglutide will be administered subcutaneously.
Cagrilintide will be administered subcutaneously.
Placebo will be administered subcutaneously.